Recent Investment Analysts’ Ratings Updates for Neurocrine Biosciences (NBIX)

Neurocrine Biosciences (NASDAQ: NBIX) recently received a number of ratings updates from brokerages and research firms:

  • 11/21/2018 – Neurocrine Biosciences is now covered by analysts at Canaccord Genuity. They set a “buy” rating and a $111.00 price target on the stock.
  • 11/16/2018 – Neurocrine Biosciences was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 11/15/2018 – Neurocrine Biosciences was downgraded by analysts at ValuEngine from a “strong-buy” rating to a “buy” rating.
  • 11/12/2018 – Neurocrine Biosciences is now covered by analysts at Leerink Swann. They set a “market perform” rating and a $110.00 price target on the stock.
  • 11/6/2018 – Neurocrine Biosciences had its price target lowered by analysts at Morgan Stanley from $145.00 to $135.00. They now have a “buy” rating on the stock.
  • 11/6/2018 – Neurocrine Biosciences was given a new $111.00 price target on by analysts at Piper Jaffray Companies. They now have a “buy” rating on the stock.
  • 11/5/2018 – Neurocrine Biosciences was given a new $150.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 11/5/2018 – Neurocrine Biosciences was given a new $140.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 10/5/2018 – Neurocrine Biosciences was given a new $115.00 price target on by analysts at Piper Jaffray Companies. They now have a “buy” rating on the stock.

NBIX stock opened at $88.27 on Monday. The stock has a market cap of $8.00 billion, a price-to-earnings ratio of -54.49, a price-to-earnings-growth ratio of 22.58 and a beta of 0.91. Neurocrine Biosciences, Inc. has a 1-year low of $67.32 and a 1-year high of $126.98.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Monday, November 5th. The company reported $0.52 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.48 by $0.04. The firm had revenue of $151.80 million for the quarter, compared to analyst estimates of $151.51 million. Neurocrine Biosciences had a return on equity of 2.54% and a net margin of 2.40%. The company’s revenue for the quarter was up 149.7% on a year-over-year basis. During the same period in the previous year, the company posted ($0.13) earnings per share. On average, equities analysts predict that Neurocrine Biosciences, Inc. will post 0.19 EPS for the current year.

In other news, Director Richard F. Pops sold 5,500 shares of the business’s stock in a transaction dated Monday, October 29th. The stock was sold at an average price of $107.13, for a total value of $589,215.00. Following the sale, the director now directly owns 37,759 shares in the company, valued at $4,045,121.67. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Gary A. Lyons sold 15,000 shares of the business’s stock in a transaction dated Friday, November 2nd. The shares were sold at an average price of $114.41, for a total value of $1,716,150.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 37,747 shares of company stock worth $4,098,171. Corporate insiders own 4.30% of the company’s stock.

Several institutional investors have recently modified their holdings of NBIX. Principal Financial Group Inc. lifted its holdings in shares of Neurocrine Biosciences by 1.6% in the first quarter. Principal Financial Group Inc. now owns 78,956 shares of the company’s stock valued at $6,547,000 after purchasing an additional 1,234 shares in the last quarter. Meeder Asset Management Inc. lifted its holdings in shares of Neurocrine Biosciences by 643.7% in the second quarter. Meeder Asset Management Inc. now owns 1,123 shares of the company’s stock valued at $110,000 after purchasing an additional 972 shares in the last quarter. Aperio Group LLC lifted its holdings in shares of Neurocrine Biosciences by 6.1% in the second quarter. Aperio Group LLC now owns 28,705 shares of the company’s stock valued at $2,820,000 after purchasing an additional 1,658 shares in the last quarter. TD Asset Management Inc. lifted its holdings in shares of Neurocrine Biosciences by 1.6% in the second quarter. TD Asset Management Inc. now owns 131,499 shares of the company’s stock valued at $12,918,000 after purchasing an additional 2,100 shares in the last quarter. Finally, Commonwealth Equity Services LLC bought a new stake in shares of Neurocrine Biosciences in the second quarter valued at about $203,000. Institutional investors own 96.88% of the company’s stock.

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease.

Featured Article: Fundamental Analysis and Individual Investors

Receive News & Ratings for Neurocrine Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply